Stock listing
NASDAQ:BOLD Boundless Bio, Inc. Stock
Home listing (NASDAQ) of Boundless Bio, Inc.
Follow Boundless Bio, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:BOLD
$2.32 USD -0.08 (-3.3%)
Close on Nov 20, 2026
- Day range
- $2.28 – $2.39 USDNov 20, 2026
- Volume
- 147,867 sharesNov 20, 2026
- Market cap
- $53.61M USDAt the close on Nov 20, 2026 · price × 23.11M shares outstanding
- 52-week range
- $0.961 – $3.16 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $344,109 USDMedian day 103,237 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:BOLD · Home | $2.32 USD | -0.08 (-3.3%) | 147,867 | $2.35 | $2.385 | $2.28 | $2.40 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:BOLD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.32 | -0.08 | -3.3% | $2.35 | $2.385 | $2.28 | 147,867 | |
| $2.40 | -0.01 | -0.4% | $2.43 | $2.43 | $2.38 | 153,051 | |
| $2.41 | 0.00 | 0.0% | $2.435 | $2.44 | $2.39 | 106,039 | |
| $2.41 | -0.09 | -3.6% | $2.50 | $2.50 | $2.40 | 137,005 | |
| $2.50 | +0.04 | +1.6% | $2.46 | $2.535 | $2.39 | 156,469 | |
| $2.46 | 0.00 | 0.0% | $2.45 | $2.47 | $2.415 | 33,586 | |
| $2.46 | +0.01 | +0.4% | $2.46 | $2.46 | $2.39 | 10,831 | |
| $2.45 | -0.01 | -0.4% | $2.46 | $2.50 | $2.40 | 119,246 | |
| $2.46 | 0.00 | 0.0% | $2.43 | $2.50 | $2.43 | 29,958 | |
| $2.46 | +0.05 | +2.1% | $2.41 | $2.52 | $2.38 | 94,045 | |
| $2.41 | +0.01 | +0.4% | $2.40 | $2.43 | $2.38 | 71,073 | |
| $2.40 | +0.02 | +0.8% | $2.41 | $2.45 | $2.40 | 138,913 | |
| $2.38 | -0.06 | -2.5% | $2.44 | $2.548 | $2.38 | 56,080 | |
| $2.44 | -0.03 | -1.2% | $2.48 | $2.50 | $2.40 | 91,155 | |
| $2.47 | -0.01 | -0.4% | $2.525 | $2.59 | $2.43 | 47,014 | |
| $2.48 | -0.02 | -0.8% | $2.51 | $2.543 | $2.453 | 57,507 | |
| $2.50 | +0.09 | +3.7% | $2.41 | $2.60 | $2.41 | 246,010 | |
| $2.41 | 0.00 | 0.0% | $2.41 | $2.43 | $2.38 | 91,087 | |
| $2.41 | +0.05 | +2.1% | $2.40 | $2.434 | $2.36 | 59,100 | |
| $2.36 | -0.08 | -3.3% | $2.41 | $2.44 | $2.345 | 34,870 | |
| $2.44 | 0.00 | 0.0% | $2.45 | $2.46 | $2.38 | 114,063 | |
| $2.44 | +0.01 | +0.4% | $2.53 | $2.565 | $2.41 | 64,263 | |
| $2.43 | +0.12 | +5.2% | $2.33 | $2.49 | $2.33 | 89,739 | |
| $2.31 | -0.03 | -1.3% | $2.38 | $2.485 | $2.31 | 219,722 | |
| $2.34 | -0.01 | -0.4% | $2.37 | $2.49 | $2.28 | 711,179 | |
| $2.35 | -0.04 | -1.7% | $2.40 | $2.525 | $2.335 | 181,976 | |
| $2.39 | -0.04 | -1.6% | $2.43 | $2.49 | $2.385 | 129,823 | |
| $2.43 | -0.12 | -4.7% | $2.55 | $2.69 | $2.39 | 463,158 | |
| $2.55 | +0.02 | +0.8% | $2.53 | $2.59 | $2.50 | 60,474 | |
| $2.53 | -0.05 | -1.9% | $2.58 | $2.64 | $2.47 | 166,793 | |
| $2.58 | -0.06 | -2.3% | $2.58 | $2.67 | $2.50 | 334,164 | |
| $2.64 | +0.07 | +2.7% | $2.58 | $2.71 | $2.562 | 116,894 | |
| $2.57 | -0.03 | -1.2% | $2.62 | $2.65 | $2.515 | 65,184 | |
| $2.60 | -0.02 | -0.8% | $2.62 | $2.66 | $2.56 | 55,060 | |
| $2.62 | +0.03 | +1.2% | $2.62 | $2.70 | $2.55 | 156,529 | |
| $2.59 | +0.08 | +3.2% | $2.49 | $2.62 | $2.49 | 163,785 | |
| $2.51 | -0.05 | -2.0% | $2.56 | $2.635 | $2.42 | 208,241 | |
| $2.56 | -0.05 | -1.9% | $2.60 | $2.62 | $2.56 | 51,995 | |
| $2.61 | -0.05 | -1.9% | $2.68 | $2.715 | $2.558 | 142,237 | |
| $2.66 | +0.06 | +2.3% | $2.61 | $2.67 | $2.59 | 255,396 | |
| $2.60 | -0.10 | -3.7% | $2.69 | $2.74 | $2.595 | 550,321 | |
| $2.70 | -0.18 | -6.2% | $2.89 | $2.89 | $2.685 | 170,128 | |
| $2.88 | +0.05 | +1.8% | $2.93 | $2.93 | $2.83 | 30,246 | |
| $2.83 | +0.02 | +0.7% | $2.80 | $2.835 | $2.75 | 133,702 | |
| $2.81 | +0.01 | +0.4% | $2.79 | $2.87 | $2.77 | 346,379 | |
| $2.80 | -0.02 | -0.7% | $2.83 | $2.83 | $2.77 | 92,212 | |
| $2.82 | +0.01 | +0.4% | $2.81 | $2.85 | $2.785 | 102,234 | |
| $2.81 | -0.03 | -1.1% | $2.83 | $2.85 | $2.81 | 23,226 | |
| $2.84 | +0.01 | +0.4% | $2.84 | $2.89 | $2.84 | 29,828 | |
| $2.83 | -0.01 | -0.4% | $2.85 | $2.85 | $2.81 | 63,841 | |
| $2.84 | -0.01 | -0.4% | $2.85 | $2.87 | $2.82 | 28,654 | |
| $2.85 | -0.01 | -0.3% | $2.86 | $2.878 | $2.83 | 48,820 | |
| $2.86 | -0.01 | -0.3% | $2.87 | $2.94 | $2.76 | 168,003 | |
| $2.87 | 0.00 | 0.0% | $2.87 | $2.89 | $2.86 | 20,000 | |
| $2.87 | -0.02 | -0.7% | $2.90 | $2.94 | $2.85 | 72,441 | |
| $2.89 | 0.00 | 0.0% | $2.89 | $2.91 | $2.85 | 81,533 | |
| $2.89 | +0.08 | +2.8% | $2.81 | $2.905 | $2.805 | 146,028 | |
| $2.81 | -0.02 | -0.7% | $2.81 | $2.94 | $2.80 | 103,237 | |
| $2.83 | -0.03 | -1.0% | $2.82 | $2.86 | $2.80 | 75,542 | |
| $2.86 | -0.055 | -1.9% | $2.91 | $2.99 | $2.86 | 46,674 | |
| $2.915 | -0.025 | -0.9% | $2.98 | $3.04 | $2.90 | 158,800 | |
| $2.94 | -0.02 | -0.7% | $2.96 | $3.00 | $2.93 | 41,264 | |
| $2.96 | -0.04 | -1.3% | $3.05 | $3.164 | $2.905 | 118,477 | |
| $3.00 | +0.10 | +3.4% | $2.91 | $3.02 | $2.91 | 157,158 | |
| $2.90 | +0.04 | +1.4% | $2.84 | $3.01 | $2.84 | 218,735 |
- Ticker
- NASDAQ:BOLD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Jun 23, 2026
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Latest deck · May 2026
Investor Presentation (May 2026)
Investor deck · 42 slides
Latest news
Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement
Jun 23, 2026
Closed $2.60 (+85.7%) on Jun 23, 2026
Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
May 8, 2026
Closed $1.44 (-5.9%) on May 8, 2026
Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting
Apr 17, 2026
Closed $1.60 (+1.3%) on Apr 20, 2026
Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026
Mar 17, 2026
Closed $1.15 (+2.7%) on Mar 17, 2026
Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Mar 9, 2026
Closed $1.14 (+0.9%) on Mar 9, 2026
Boundless Bio to Participate in the Leerink Global Healthcare Conference
Mar 4, 2026
Closed $1.14 (+0.9%) on Mar 4, 2026
Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Feb 5, 2026
Closed $1.09 (+3.8%) on Feb 5, 2026
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
Jan 20, 2026
Closed $1.23 (-0.8%) on Jan 20, 2026
Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference
Nov 24, 2025
Closed $1.11 (-1.8%) on Nov 24, 2025
Boundless Bio, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 9 in the last 12 months · 26 in all · newest Jun 23, 2026 · oldest 2024
- Decks
- 1 deck · latest May 2026
Where Boundless Bio, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:BOLD · Home listing · This page | NASDAQ | United States | USD |
| BOATS:BOLD | BOATS | United States | USD |
Valuation
Price/book 0.9× against a median of 0.9×: 4th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$9.28M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.9×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.65
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Boundless Bio, Inc. · NASDAQ:BOLD | US$53.61M | −US$9.28M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.65 |
| Cognition Therapeutics, Inc. · NASDAQ:CGTX | US$55.37M | US$25.10M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | 2.28 |
| AB Science SA · EURONEXT:AB | US$55.19M | US$50.54M | n/a | 39.2× | n/a | n/a | −132.6% | n/a | n/a |
| Azora Therapeutics, Inc. · NASDAQ:AZR | US$55.00M | US$33.00M | n/a | n/a | n/a | n/a | n/a | n/a | 1.00 |
| Island Pharmaceuticals Ltd · ASX:ILA | US$54.84M | US$46.32M | n/a | 248× | n/a | 6.2× | n/a | 0.0× | n/a |
| Anavex Life Sciences Corp. · NASDAQ:AVXL | US$54.83M | −US$63.50M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 2.39 |
| Nordicus Partners Corp · OTC:NORD | US$54.44M | US$54.44M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.45 |
| Xilio Therapeutics, Inc. · NASDAQ:XLO | US$53.40M | −US$62.82M | n/a | −1.1× | n/a | 0.8× | −20.9% | 0.1× | 0.76 |
| Impact BioMedical, Inc. · AMEX:IBO | US$53.31M | US$53.29M | 33.0× | 1,402× | n/a | 5.3× | n/a | 0.0× | 0.06 |
| XBiotech Inc. · NASDAQ:XBIT | US$52.74M | −US$52.29M | n/a | n/a | n/a | 0.4× | n/a | 0.0× | 0.52 |
| Bonus Biogroup Ltd. · TASE:BONS | US$52.22M | US$54.52M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Median of the others | US$54.64M | US$39.66M | 33.0× | 143× | 0.9× | −76.8% | 0.0× | 0.76 |
Forecasts
1 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 4.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.71 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Jessica Oien | Chief Legal Officer |
| Angela Pietrofeso | Vice President, Clinical Operations |
| David Hinkle | Senior Vice President, Finance & Controller |
| Jonathan Lim | Chairman and Co-Founder |
| Meredith Wesley | Chief Human Resources Officer |
Board
| Director | Role |
|---|---|
| Jonathan Lim | Chairman and Co-Founder |
| James Jamie Christensen | Director |
| Jennifer Lew | Director |
| Nancy Whiting | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −0.4% |
| Q2 2026 | Aug 7, 2026 | −0.7% |
| Q1 2026 | May 8, 2026 · Before open | −5.9% |
| Q4 2025 | Mar 26, 2026 | −1.8% |
| Q3 2025 | Nov 5, 2025 · Before open | −3.1% |
| Q2 2025 | Aug 5, 2025 · Before open | −1.7% |
| Q1 2025 | May 9, 2025 · Before open | −4.0% |
| Q4 2024 | Mar 27, 2025 | −1.3% |
| Q3 2024 | Nov 7, 2024 · After close | +5.4% |
| Q2 2024 | Aug 12, 2024 · After close | +2.8% |
All 12 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 13, 2024 · Before open | +10.8% |
| Q4 2023 | Feb 28, 2024 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (May 2026) | Investor deck | 42 slides | May 2026 |
IPO
Priced at US$16.00 a share on Mar 27, 2024.
- Price
- US$16.00 a share
- Shares offered
- 6,250,000 shares of common stock
- Offering size
- US$100 million
- Underwriters' option
- Up to 937,500 more shares
- Underwriters
- Goldman Sachs & Co. LLC, Leerink Partners, Piper Sandler, Guggenheim Securities · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Sep 1, 2023 |
| Filed publicly | Mar 6, 2024 |
| Amended once | Mar 21, 2024 |
| Shares registered with an exchange | Mar 22, 2024 |
| Declared effective by the SEC | Mar 27, 2024 |
| Final prospectus, with the price | Mar 28, 2024 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Mar 28, 2024 |
| EFFECT · Notice that a registration is effective | Mar 27, 2024 |
| CERT · Exchange's certificate of listing | Mar 27, 2024 |
| CORRESP · Letter to the SEC | Mar 25, 2024 |
| CORRESP · Letter to the SEC | Mar 25, 2024 |
| 8-A12B · Registration of shares for listing on an exchange | Mar 22, 2024 |
| S-1/A · Registration statement, amended | Mar 21, 2024 |
| CORRESP · Letter to the SEC | Mar 15, 2024 |
| UPLOAD · Letter from the SEC | Mar 13, 2024 |
| CORRESP · Letter to the SEC | Mar 8, 2024 |
All 18 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Mar 6, 2024 |
| S-1 · Registration statement | Mar 6, 2024 |
| UPLOAD · Letter from the SEC | Jan 29, 2024 |
| DRS/A · Draft registration statement, amended | Jan 23, 2024 |
| DRSLTR · Letter to the SEC with a draft | Oct 11, 2023 |
| DRS/A · Draft registration statement, amended | Oct 11, 2023 |
| UPLOAD · Letter from the SEC | Sep 29, 2023 |
| DRS · Draft registration statement | Sep 1, 2023 |
Open IPO · From the cover of the final prospectus (424B4) filed Mar 28, 2024
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Cost of revenue | 1.25M | 1.09M | 957.0K | 942.0K | 682.0K | |||
| Gross profit | -1.25M | -1.09M | -957.0K | -942.0K | -682.0K | |||
| Research and development | 44.8M | 55.3M | 42.6M | 37.2M | 19.3M | 104.4M | 75.9M | 48.8M |
| Selling, general and administrative | 18.7M | 18.0M | 12.2M | 9.31M | 6.02M | 30.0M | 17.3M | 11.3M |
| Operating income | -63.6M | -73.3M | -54.8M | -46.5M | -25.3M | -134.4M | -93.2M | -60.0M |
| Depreciation and amortization | 1.25M | 1.09M | 957.0K | 942.0K | 682.0K | 7.46M | 3.75M | 1.58M |
| EBITDA | -62.3M | -72.2M | -53.8M | -45.5M | -24.6M | -126.9M | -89.4M | -58.5M |
| Income before tax | -58.2M | -65.4M | -49.4M | -45.9M | -25.2M | -128.8M | -92.5M | -59.7M |
| Income tax | 0 | 0 | -5.28M | -668.0K | -96.0K | 5.55M | -2.25M | 378.0K |
| Net income | -58.2M | -65.4M | -49.4M | -45.9M | -25.2M | -128.8M | -90.2M | -59.7M |
| Earnings per share, basic | -2.60 | -3.85 | -40.65 | -2.06 | -1.13 | -2.93 | -3.40 | -5.59 |
| Earnings per share, diluted | -2.60 | -3.85 | -40.65 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 17.9M | 26.6M | 23.7M | 11.0M | 34.3M | 144.3M | 39.0M | 36.4M |
| Short-term investments | 89.7M | 125.5M | 97.0M | 55.8M | 38.7M | 270.0M | 94.6M | 68.5M |
| Current assets | 109.6M | 154.4M | 124.2M | 68.0M | 74.6M | 419.8M | 137.0M | 108.4M |
| Property, plant and equipment | 3.22M | 4.32M | 2.57M | |||||
| Goodwill | 3.63M | 3.63M | 3.63M | |||||
| Total assets | 157.1M | 206.4M | 129.9M | 76.8M | 113.7M | 472.6M | 178.7M | 142.1M |
| Accounts payable | 1.49M | 1.27M | 2.22M | 1.40M | 1.07M | 8.12M | 3.85M | 2.42M |
| Current liabilities | 12.5M | 8.13M | 9.36M | 7.73M | 3.87M | 23.9M | 17.7M | 12.6M |
| Total debt | 49.0M | 47.6M | 2.19M | 5.18M | 377.0K | 7.07M | 7.18M | 2.75M |
| Total liabilities | 58.4M | 55.8M | 9.36M | 158.5M | 151.9M | 29.8M | 22.1M | 22.7M |
| Shareholders' equity | 98.7M | 150.6M | -127.1M | -81.7M | -38.2M | 442.8M | 156.6M | 119.4M |
| Shares outstanding | 22.4M | 22.3M | 1.25K | 22.2M | 22.2M | 44.0M | 26.6M | 10.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -46.7M | -60.8M | -46.9M | -39.6M | -23.2M | -108.0M | -84.5M | -49.0M |
| Capital spending | -546.0K | -2.54M | -633.0K | -1.07M | -2.03M | -11.6M | -7.55M | -16.7M |
| Free cash flow | -47.2M | -63.4M | -47.5M | -40.7M | -25.3M | -119.6M | -92.1M | -65.7M |
| Cash from investing | 37.8M | -26.1M | -38.3M | 16.1M | -59.3M | -185.0M | -33.4M | -62.0M |
| Cash from financing | 141.0K | 89.8M | 97.9M | 126.0K | 105.5M | 398.5M | 120.6M | 75.4M |
| Share buybacks | 141.0K | 110.0K | -144.3M | -39.0M | -36.4M | |||
| Change in cash | -8.72M | 2.88M | 12.8M | -23.3M | 23.0M | 105.4M | 2.61M | -35.7M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 10, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Nov 4, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Nov 3, 2026 | Offer document | SEC |
| S-4/A · Registration statement, amended | Oct 30, 2026 | Offer document | SEC |
| 4 · Change in ownership | Oct 29, 2026 | Insider trade | SEC |
All 167 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 425 | Oct 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 26, 2026 | Insider trade | SEC |
| 425 | Oct 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Oct 20, 2026 | Insider trade | SEC |
| S-4 · Registration statement | Oct 8, 2026 | Offer document | SEC |
| DRS · Draft registration statement | Aug 31, 2026 | Offer document | SEC |
| 425 | Aug 28, 2026 | Other filings | SEC |
| 8-K · Current report | Aug 28, 2026 | Material contract | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 29, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 29, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 29, 2026 | Insider trade | SEC |
| 425 | Jun 23, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 23, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 17, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 13, 2026 | Financing | SEC |
| 10-K · Annual report | Mar 9, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 9, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 4, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 23, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 23, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2025 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Apr 11, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 8, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 8, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 1, 2025 | Material contract | SEC |
| S-3 · Registration statement | Apr 1, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 27, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 27, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jan 23, 2025 | Other filings | SEC |
| 8-K · Current report | Dec 12, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 7, 2024 | Results | SEC |
| SC 13D · Big-stake notice | Oct 29, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Oct 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 15, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 20, 2024 | Management or board change | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2024 | Results | SEC |
| SC 13G · Big-stake notice | Apr 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Apr 12, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Apr 10, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Apr 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 2, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 29, 2024 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 28, 2024 | Offer document | SEC |
| 424B4 · Prospectus | Mar 28, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Mar 28, 2024 | Other filings | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 27, 2024 | Insider trade | SEC |
| CERT · Exchange's certificate of listing | Mar 27, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 25, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 25, 2024 | Other filings | SEC |
| 8-A12B · Registration of shares for listing on an exchange | Mar 22, 2024 | Other filings | SEC |
| S-1/A · Registration statement, amended | Mar 21, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 15, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 13, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 8, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 6, 2024 | Other filings | SEC |
| S-1 · Registration statement | Mar 6, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Jan 29, 2024 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Jan 22, 2024 | Offer document | SEC |
| DRSLTR · Letter to the SEC with a draft | Oct 11, 2023 | Other filings | SEC |
| DRS/A · Draft registration statement, amended | Oct 11, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Sep 29, 2023 | Other filings | SEC |
| DRS · Draft registration statement | Sep 1, 2023 | Offer document | SEC |
| D | Aug 14, 2023 | Other filings | SEC |
| D | May 4, 2021 | Other filings | SEC |
| D | Mar 12, 2020 | Other filings | SEC |
Cap table
Built by 6ix from Boundless Bio, Inc.’s releases
- Common shares
- 23,108,935
- Fully diluted
- 23,108,935
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 23,108,935 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 23,108,935 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kristina Burow Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Jan 30, 2025); Neumora Therapeutics, Inc. (Director · Since at least Sep 14, 2023); Scholar Rock Holding Corporation (Director · Since at least May 23, 2018); Metacrine Inc (Director · Sep 15, 2020 – May 24, 2021 · Past); Beam Therapeutics Inc. (Director · Feb 5, 2020 – Jun 6, 2023 · Past); Vir Biotechnology, Inc. (Director · Oct 10, 2019 – May 21, 2020 · Past); Gossamer Bio, Inc. (Director · Feb 7, 2019 – Jun 8, 2023 · Past); Unity Biotechnology Inc (Director · May 2, 2018 – Jun 24, 2021 · Past); Receptos Inc (Director · Aug 25, 2015 – Aug 25, 2015 · Past) | Director · Since at least Mar 27, 2024 |
| Jennifer Lew Other companies: Annexon, Inc. (EVP & CHIEF FINANCIAL OFFICER · Since at least Jul 23, 2020); Aduro Biotech Inc (Chief Financial Officer · Apr 14, 2015 – May 1, 2019 · Past); Dynavax Technologies Corporation (VP, Finance & PAO · Jan 31, 2012 – Feb 5, 2013 · Past) | Director · Since at least Mar 27, 2024 |
| Christian Hassig Other companies: Sierra Oncology Inc (Chief Scientific Officer · Feb 1, 2018 – Mar 4, 2019 · Past) | Chief Scientific Officer · Since at least Mar 27, 2024 |
| David Hinkle Other companies: Receptos Inc (Sr. Dir. Fin, Cntrlr & CAO · May 8, 2013 – May 8, 2013 · Past) | Senior Vice President, Finance & Controller · Since at least Oct 11, 2024 |
| Jessica Oien Other companies: Cidara Therapeutics Inc (General Counsel & Secretary · Dec 3, 2018 – Mar 17, 2021 · Past) | Chief Legal Officer · Since at least Mar 27, 2024 |
| Angela Pietrofeso | Vice President, Clinical Operations · Since at least Nov 4, 2026 |
| Christine Brennan | Director · Since at least Mar 27, 2024 |
| James Jamie Christensen | Director · Since at least Mar 27, 2024 |
| Jonathan Lim | Chairman and Co-Founder · Since at least Nov 4, 2026 |
| Meredith Wesley | Chief Human Resources Officer · Since at least Nov 4, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Nancy Whiting | Director · Since at least Nov 4, 2026 |
| Neil Abdollahian | Chief Business Officer · Mar 27, 2024 – Aug 19, 2024 · Past |
Log in to ask 6ix AI your own questions about Boundless Bio, Inc.